Neurológia pre prax 6/2018
Porovnanie bezpečnosti a monitoringu DMD liekov prvej eskalačnej línie – dimetylfumarát, fingolimod, kladribin a okrelizumab
Treatment of relapsing-remitting multiple sclerosis (RR-MS) has been progressing tremendously over recent years. In the light of expanding treatment options for patients with multiple sclerosis, the issue of safety and monitoring has become an important part of the decision-making process when choosing a suitable treatment. Properly selected therapy is important for patients’ adherence and effective therapy. This article focuses on the safety and monitoring of patients treated with DMDs of the „first-and-a-half” escalation line.
Keywords: multiple sclerosis, safety, monitoring